About new osteoporosis medicines - From 2013 to 2016 and after -

Abstract

　The essence of the osteoporosis treatment is to control bone metabolic turnover. Since the approval of alendronate in 1993, various osteoporosis medicines including denosumab and teriparatide have been developed, and we have become able to control bone metabolic turnover to some extent. Furthermore, abaloparatide which is a facilitator of bone formation was approved by the Food and Drug Administration of the United States in 2017, and romosozumab which is a facilitator of bone formation without accelerating bone turnover is simply waiting for approval. The arrival of a new osteoporosis medicine which is more effective than what have been using has been much a waited to accomplish the “goal-directed treatment” of osteoporosis. Osteoporosis treatment will advance further with the arrival of such drugs with higher bone anabolic potential. I will explain osteoporosis medicines released 2013 and after, including these 2 drugs.